Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Shares Traded Last Trade
  -1.10 -2.4% 44.70 580,524 16:35:00
Bid Price Offer Price High Price Low Price Open Price
44.30 44.90 45.40 43.60 44.60
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -2.93 -0.99 128
Last Trade Time Trade Type Trade Size Trade Price Currency
16:35:00 UT 3,071 44.70 GBX

Futura Medical (FUM) Latest News

More Futura Medical News
Futura Medical Investors    Futura Medical Takeover Rumours

Futura Medical (FUM) Discussions and Chat

Futura Medical Forums and Chat

Date Time Title Posts
16/6/202115:56FUM delivering on sex,pain and rock'n'roll11,686
20/5/202110:01FUTURA a winner for 20159,917
24/3/202116:51one million6
23/3/202120:20fum reality42
21/1/201909:54www.bluediamondcondom.com59

Add a New Thread

Futura Medical (FUM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2021-06-17 15:35:0044.703,0711,372.74UT
2021-06-17 15:25:3244.90208.98O
2021-06-17 15:15:5244.852,203988.05O
2021-06-17 15:10:5044.215,0002,210.56O
2021-06-17 14:58:4545.00995447.75O
View all Futura Medical trades in real-time

Futura Medical (FUM) Top Chat Posts

DateSubject
17/6/2021
09:20
Futura Medical Daily Update: Futura Medical Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker FUM. The last closing price for Futura Medical was 45.80p.
Futura Medical Plc has a 4 week average price of 43.60p and a 12 week average price of 42.30p.
The 1 year high share price is 83.50p while the 1 year low share price is currently 12.25p.
There are currently 287,070,971 shares in issue and the average daily traded volume is 509,421 shares. The market capitalisation of Futura Medical Plc is £128,320,724.04.
04/6/2021
10:05
bag158s: Broker Liberum has raised FUM price target to 102 now
13/5/2021
16:26
broomrigg: Futura Medical PLC's (LON:FUM) receipt of full EU approval for MED3000 has prompted house broker Liberum to upgrade its share price target to 80p from 65p. Approval removes the last hurdle to signing meaningful commercial agreements, in the view of the broker. Liberum added its forecasts have now been upgraded to account for over-the-counter rather than prescription status, which drives longer-term upgrades and makes for a more valuable commercial proposition. "We expect the start of the US study, regulatory approvals in other regions and commercial deals over the coming 6-12 months to crystalise further value and drive a re-rating."
01/5/2021
09:38
lbo: Mike unfortunately all the products have failed now too and the patents are expired or nearly expired. And please don’t mention CBD. Another attempt to pull the wool over shareholders eyes to try get them to keep paying the BoD salaries. https://onlinelibrary.wiley.com/doi/10.5694/mja2.51014 But Mike you called it right about them trying to ramp up the share price mikethebike4 - 09 Jan 2019 - 12:24:31 - 4773 of 9529 nobody disputes csd & med & tpr are very good, disruptive products - it's just that the BoD has signally failed in the past 17 years to capitalise on csd and still refuses to currently, despite loads of so-called distributors raring to go to shareholders great mis-fortune history is probably repeating itself despite the fact that it is in their interest to get the share price up to £1 - see outstanding share options https://www.futuramedical.com/content/investors/share_statistics.asp
15/4/2021
16:15
lbo: Maybe some doubts have started to creep in about what the final wording of the EU certification will be. So makes sense to convert now ahead of the official certification in May if they are looking to realise some of that £3m profit they were given on a £2m loan convertible into equity at 20/22p. If MED3000 is approved as a Class 2b device but its not fully OTC in all the EU regions like Sildenafil that also would be different to what some have led investors to believe. And if MED3000 will require a pharmacy consultation in the UK like Sildenafil then is that really OTC. Or maybe as its just a placebo Medical device with no active drug that is given full OTC status then the marketing claims are going to be narrower then hoped eg just like CSD500 an erectogenic device and its use can lead to a firmer erection but it cannot be claimed to be equivalent to an ED drug treatment. But all that aside. What is also known is the revenue potential that Futura keeps touting is based on Cello and IPSOS research from years ago. Also based on a different product MED2002. The pricing is also out of date and at price per dose of £2.50 today it would only equate to $3.45 now. Not $5 which is what was used 4 years ago when the original research was carried out. It would also have inspired more confidence if Ms Yang Liu had just said they were committed to being long term shareholders and wouldn’t be selling any of the shares at the current share price. Especially as she believed the share price was still undervalued. But unfortunately she didn’t clarify her intentions. If they haven’t sold any shares then they should be over 3% so they will have to declare their shareholding. But if they have sold the warrant shares then they will be under 3% and won’t have to notify the market if they keep selling. Also if they are truly committed long term shareholders then they wont sell any warrant shares at all and they will take part in a rights issue to help raise the further funds needed for the FDA study. If they are really committed and want more shares then why don’t they even underwrite a fundraising at the current share price? (Or do they only want shares when they are issued at 20/22p?)
06/4/2021
14:56
lbo: I am not referring to the warrants. Please see page 40 in the annual report. Management if they are so sure about the current share price under valuing the company then could exercise all the options they have that can be exercised at the moment and not sell them if they think the share price will continue to rise. It’s ironic they are not rushing to exercise when the company could do with all the cash it can get for the FDA study and especially after James Barder said last week: "I am appreciative of the continued support from Atlantis Investment Management Limited”. Where is the equivalent management support? https://www.futuramedical.com/media/2251/futuramedical-ar2019.pdf DIRECTORS’ INTERESTS IN SHARE OPTIONS The Board uses share options to align Executive Directors’ and employees’ interests with those of shareholders in order to provide incentives and reward them based on improvements in Group performance. All share options were granted with an exercise price at or above market value on the date of grant. The main vesting condition of the share options is that the Director remains employed with the Group as at the date of exercise or continues to provide consultancy services as at the date of exercise. The share options of the Directors under the Futura Medical plc Enterprise Management Incentive Scheme are set out in the Annual report https://www.stocksahoy.co.uk/share/FUM.L/directorsdeals
29/3/2021
15:54
keifer derrin: personally I think the big pharmas will wait for the patent. But if they do wait and the patent is extended until 2039 it will cost them a lot more to buy FUM, which suits me fine For me, FUM do not have a great track record and have a few failed products. I cannot believe we've still not heard anything about TPR100. I've even emailed them about it and nothing. But they have finally got a product and the recent spike in the share price has made me a lot of money and I will be holding for FUM to make me even more money.....
29/3/2021
11:40
lbo: Please go back and DYOR on what Futura and the Directors themselves have said. Kinwah I agree nobody knows where the share price will go in the short term and I will be delighted if its upwards and sustained by real royalties not deals with big or even small distributors that eventually all come to nothing. As the expression goes. Fool shareholders once with CSD500 then shame on Futura but fool them twice then shame on shareholders. September 2019 interview with the FD https://www.labiotech.eu/interview/futura-medical-angela-hildreth/ While the product had been approved, two major partners had walked out of partnerships to commercialize it for strategic reasons. One was Durex, the other its competitor Church & Dwight. “If you have the two biggest condom brands in the world kind of doing a deal with you and then handing you the rights back, where do you go from there?” Hildreth pointed out. “When you invest a lot of time and effort into something, it’s very hard to come to the realization that without that big brand behind you all you’re going to do is disappoint.” Futura Medical had to turn its attention to another treatment for erectile dysfunction, this time in the form of a gel. The company signed a deal with GSK. However, the pharma ended dropping the project as it didn’t fit its priorities. December 2019 Futura Medical Erectile Dysfuction Drug MED2005 Fails To Beat Placebo https://www.advfn.com/stock-market/london/FUM/stock-news/81319001/futura-medical-erectile-dysfuction-drug-med2005-fa Whilst the overall design is similar to that of the previous large phase 3 FM57 study that recruited approximately 1000 patients, no placebo (sham) cohort is required https://uk.advfn.com/stock-market/london/futura-medical-FUM/share-news/Futura-Medical-PLC-US-FDA-Agreement-for-Confirmato/84630885
28/3/2021
15:34
lbo: I will say it again. I have been a shareholder for many years and would love to see the share price continue a sustainable share price rise based on on the back of starting to generate real royalties. https://uk.advfn.com/cmn/fbb/thread.php3?id=33313581&from=3443 Even the house brokers Liberum only have a price target of 68p now based on building in a lot of future optimistic assumptions. So why some of you seem only motivated to personally focus on me instead of focusing on and answering the real fundamental questions about Futura and MED3000 is also very questionable. The MHRA also had worries about making an ED treatment fully OTC so they decided that Sildenafil can only be sold from pharmacies following a consultation with the pharmacist. Pharmacists then determine whether treatment is appropriate or if further consultation with a general practitioner is required. https://hcp.viagraconnect.co.uk/sites/default/files/2018-02/Essential%20Information%20for%20Supply%20of%20Viagra%20Connect_0.pdf https://www.healthline.com/health-news/sanofi-lilly-seek-FDA-approval-Cialis-OTC-052814 https://ajp.com.au/news/division-over-scheduling-decisions/ https://hbw.pharmaintelligence.informa.com/RS150904/Viagra-Connect-To-Launch-In-Ireland-Following-Rx-to-OTC-Switch
25/3/2021
07:03
lbo: You say you are not a short term day trader but then make comments that a fleeting intraday share price is how to define creating real medium to long term shareholder value on the back of hyped news. Futura has been here before and had a European CE mark approval awarded for its similar product CSD500. And licensed and launched that product in the EU well the Netherlands and many other territories. Yet here Futura are still years later not generating any Royalties or Revenues. That harsh reality does for a lot of shareholders deserve silence. What else had to be said about it. At least until more no new news is released about the failed MED2005 placebo now called MED3000 getting a CE mark. As if CE marks are guaranteed to generate considerable sales. Not something they look at in the low bar criteria needed for certain non invasive devices in Europe. Durex play and Ky warming also have CE marks. But something real shareholders definitely would need to consider is if this so called new news and share price rise is any different this time and will lead to real value creation and sustained share price appreciation. It was also noteworthy after all the so called news neither Trinity nor Liberum updated their target prices to multiples of 40p. I also gave links to that too. https://assets.publishing.service.gov.uk/media/55cb331ae5274a5473000025/Reckitt_Benckiser_-_K-Y_brand_final_report_Appendices_and_Glossary.pdf The medical device is classified in one of four classes, based on rules using criteria that include invasiveness, duration of continuous contact, nature of tissue contact and whether the device is active or non-active. Most personal lubricants belong to class IIa
24/3/2021
22:29
lbo: How is saying the share price has fallen all the way down from 95p is a positive? Thats a negative. The chartists, day traders or whatever you want to call them said all the rest about where they thought the share price was going on supposed technicals. Nothing to do with fundamentals. The last fundraising had to be at 8p it was so bad. I also posted all the links to the pie in the sky potential for this product and clearly showed they were wrong when they did the same on CSD500 a few years ago. I also posted the interview from Labiotech.eu with Angela Hildreth about how bad things got. None of which was positive. Again you only seem to see what you want and only reposting some of my posts. You are displaying clear signa of something called selective reinforcement bias.
Futura Medical share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210618 02:55:14